Cannabichromene Safety in Rheumatoid Arthritis

Summary

For this quantitative study, the investigators will collect data on human safety and side-effects of Cannabichromene (CBC) and whether CBC reduces blood inflammatory markers and Rheumatoid Arthritis (RA) disease activity. The participants will participate in an ABAB design with 2 doses of CBC across the A phases. They will attend 5 in-person clinic visits where they will have physical evaluations, complete self-report forms, and have blood drawn for the following tests: hs-CRP, ESR, IL-6, TNF, Complete Blood Count \[CBC\], and CMP.

Timeline

Start

2028-07-15

Primary completion

2030-05-31

Completion

2030-05-31

Outcome

Outcome not reported

Stopped (Enrollment): “This study was put on clinical hold with the FDA prior to beginning enrollment due to insufficient preclinical evidence.”

Drugs

Indications